The regulatory survey on the impact and vision of GMP facilities that has been performed from June to September has been finalized. A total of 55 facilities over 13 countries responded to our survey, mainly academic medical centers. In 2013, 1174 patients were treated in the 41 facilities that shared their production numbers, of which 45% was treated with an ATMP during a clinical trial. Most patients (55%) were treated under other regulatory framework like hospital exemption (HE) and named patient use. The first results of the survey were presented on the ESGCT (European Society of Gene and Cell Therapy) meeting that was held 23-26 October.